PE anti-human CD117 (c-kit) Antibody

Product Details

Verified Reactivity

Human

Reported Reactivity

Cynomolgus, Cow

Antibody Type

Monoclonal

Host Species

Mouse

Immunogen

MOLM-1 megakaryocytic cell line

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)

Preparation

The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.

Concentration

Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)

Storage & Handling

The CD117 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested
SB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser

Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Application Notes

The 104D2 antibody does not block binding of c-Kit ligand. Additional reported applications (for the relevant formats) include: immunoprecipitation¹, immunofluorescence microscopy¹, and spatial biology (IBEX)^4,5.

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)

1. Broudy VC, et al. 1999. Blood 94:1979. (IF, IP)
2. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
3. Nagano M, et al. 2007. Blood 110:151. (FC) PubMed
4. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
5. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Matkovic Leko I, et al. 2023. Nat Protoc. . PubMed
2. Sun J, et al. 2008. J Biol Chem. 283:27444. PubMed
3. Sun J, et al. 2018. Oncogenesis. 7:48. PubMed
4. Zhao Y, et al. 2016. Cell Rep. 16:2003-2016. PubMed
5. Sun J, et al. 2009. J Biol Chem. 284:11039. PubMed
6. Niwa A, et al. 2011. PLoS One. 6:e22261. PubMed
7. Cho K, et al. 2017. Biochem Biophys Res Commun. 10.1016/j.bbrc.2017.04.141. PubMed
8. Taguchi A, et al. 2017. Cell Stem Cell. 21:730. PubMed
9. Cruse G, et al. 2015. Mol Biol Cell. 26:1711. PubMed
10. Lecluze E, et al. 2020. Hum Reprod. 35:1099. PubMed
11. Shen C, et al. 2021. Front Immunol. 12:680055. PubMed
12. Zhang J, et al. 2019. Dev Cell. 48:329. PubMed
13. Suzuki S, et al. 2021. STAR Protocols. 2:100683. PubMed
14. Schielke L, et al. 2022. Front Immunol. 13:916701. PubMed
15. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
16. Zeng Z, et al. 2021. Nat Commun. 12:3641. PubMed
17. Smith-Díaz CC, et al. 2021. Front Oncol. 11:709543. PubMed
18. López-Sanz C, et al. 2022. STAR Protoc. 3:101755. PubMed
19. Bender R, et al. 2016. PLoS Pathog. 12: 1005641. PubMed
20. Zhang Y et al. 2018. Cell stem cell. 23(4):516-529 . PubMed
21. Pan C, et al. 2019. Int J Mol Med. 44:1629. PubMed
22. Bennstein SB, et al. 2020. eLife. 9:e55232.. PubMed
23. Wang G, et al. 2018. Int J Mol Med. 41:791. PubMed
24. Mpakou V, et al. 2021. Exp Ther Med. 1.010416667. PubMed
25. Samuel RM, et al. 2020. Cell Stem Cell. 27:876. PubMed

RRID

AB_314982 (BioLegend Cat. No. 313203)
AB_314982 (BioLegend Cat. No. 313204)

Antigen Details

Structure

Growth factor receptor with tyrosine kinase activity, subclass III, approximately 145 kD

Distribution

Pluripotent hematopoietic progenitor cells (approximately 1-4% bone marrow cells), mast cells, acute myeloid leukemic cells (AML)

Function

Growth factor receptor for stem cell factor. Induces proliferation and survival of primitive hematopoietic progenitors. Potent inducer of proliferation in erythroid-committed progenitor cells. Defects in CD117 have been linked to severe anemia and a decreased number of hematopoietic progenitor cells.

Ligand/Receptor

c-Kit ligand

Modification

Multiple phosphorylation sites

Cell Type

Embryonic Stem Cells, Hematopoietic stem and progenitors, Leukemia, Mast cells, Mesenchymal Stem Cells

Biology Area

Immunology, Stem Cells

Molecular Family

CD Molecules

Antigen References

1. Giebel LB, et al. 1992. Oncogene 7:2207.
2. Furitsu T, et al. 1993. J. Clin. Invest. 92:1736.

Gene ID

3815 View all products for this Gene ID

Specificity (DOES NOT SHOW ON TDS):

CD117

Specificity Alt (DOES NOT SHOW ON TDS):

CD117

App Abbreviation (DOES NOT SHOW ON TDS):

FC,SB

UniProt

View information about CD117 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

What type of PE do you use in your conjugates?

We use R-PE in our conjugates.

If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Other Formats

Certificate of Analysis